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Abstract 
Background: Artesunate + sulfadoxine-pyrimethamine (AS + SP) has been the first-line treatment and artemether-
lumefantrine (AL) the second-line treatment for uncomplicated falciparum malaria in Yemen since 2005. This paper 
reports the results of studies conducted to monitor therapeutic efficacy of these two drugs in sentinel sites in Yemen.
Methods: Eight therapeutic efficacy studies were conducted in six sentinel sites during the period 2009–2013 in 
Yemen. Five studies were for the evaluation of AS + SP (total of 465 patients) and three studies (total of 268 patients) 
for the evaluation of AL. The studies were done according to standard WHO protocol 2009 with 28-day follow-up.
Results: In the evaluation of AS + SP, the PCR-corrected cure rate was 98 % (95 % CI 92.2–99.5 %) in one site and 
100 % in all of the other four sites. In the sites where AL was evaluated, the PCR-corrected cure rate was 100 % in all 
the sites. All patients were negative for asexual parasitaemia on day 3 in both the AS + SP and the AL groups. There 
was a higher rate of clearance of gametocytaemia in the AL-treated group when compared with the AS + SP groups 
from day 7 onwards.
Conclusion: AS + SP remains the effective drug for uncomplicated falciparum malaria in Yemen. AL is also highly 
effective and can be an appropriate alternative to AS + SP for the treatment of falciparum malaria. AL demonstrated a 
higher efficacy in clearing microscopic gametocytaemia than AS + SP.
Trial registration: Trial registration number ACTRN12610000696099
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Background
There are four major epidemiological strata of malaria 
in the Republic of Yemen. These are coastal plain, foot-
hills, mountains, and the island of Socotra. Malaria-free 
zones include the mountain plateau and arid slopes from 
the highlands to the desert. In 2013, 25 % (6,100,000) of 
a total population of 24,400,000 lived in areas of high 
transmission (>1 case/1000), 53  % (12,900,000) in areas 
of low transmission (0–1 case/1000) and 22 % (5,400,000) 
in malaria-free areas [1]. Most of the cases (99 %) are due 
to Plasmodium falciparum and only 1 % due to Plasmo-
dium vivax. No indigenous malaria has been detected in 
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Socotra since 2006 [2]. Malaria transmission in Yemen 
differs between the regions. In the coastal areas, peak 
transmission occurs in winter (October–April), while 
in the mountainous hinterland areas it usually peaks in 
summer (May–September). However, in highland areas 
located above 2000  m above sea level, transmission 
occurs throughout the year [3]. The geographic location 
of Yemen makes it highly relevant to the malaria elimi-
nation efforts of its northern neighbour (Saudi Arabia) 
and for the prevention of re-introduction of malaria of 
its eastern neighbour (Oman). Given that Yemen con-
tributes over 98 % of the malaria burden of the Arab Pen-
insula, the achievement of the targets of ‘malaria Free 
Arabian Peninsula Initiative’ depends heavily on the dis-
ease situation in Yemen [2].
Most of the early studies on anti-malarial drug efficacy 
that were carried out in Yemen in the 1980s and the 1990s 
were done in the southern parts of the country. These 
were mainly in vivo studies based on the standard WHO 
seven-day test to assess response of falciparum malaria 
to chloroquine (CQ). The studies, which were conducted 
by WHO consultants for malaria control, reported no 
significant levels of CQ resistance at the time [4]. In 
2002, the National Malaria Control Programme (NMCP) 
established sentinel sites for monitoring the therapeutic 
efficacy of anti-malarial drugs to P. falciparum based on 
the earlier versions of standard WHO protocol [5]. Since 
then, 17 studies have been conducted by the NMCP, cov-
ering CQ, sulfadoxine-pyrimethamine (SP) and amo-
diaquine (AQ) monotherapy and more recently, the 
artemisinin-based combinations of artesunate + amodi-
aquine (AS +  AQ), artesunate +  sulfadoxine-pyrimeth-
amine (AS  +  SP) and artemether  +  lumefantrine (AL) 
(Adel Aljasary, pers. comm.). The first therapeutic tests 
on CQ were conducted in 2002–03 [6, 7] based on the 
2001 WHO protocol [5]. By 2004, these tests revealed 
high rates of treatment failures with CQ and the results 
were summarized in WHO’s report on global monitor-
ing of susceptibility of Plasmodium falciparum to anti-
malarial drugs, which cited nine therapeutic efficacy 
studies in Yemen with median treatment failure rate of 
42.4 % (range 9–57 %) for CQ and one trial for SP with no 
treatment failure [8].
The emergence and spread of drug-resistant malaria 
has been a major factor in the global resurgence of falci-
parum malaria in the 20th Century. Drug resistance has 
been implicated in the spread of malaria to new areas 
and re-emergence of malaria in areas where the disease 
had been eliminated. Drug resistance has also played a 
significant role in the occurrence and severity of epidem-
ics in some parts of the world [9]. In Yemen, the spread 
of CQ-resistant falciparum malaria was associated with 
deterioration of the malaria situation in terms of disease 
prevalence and clinical impact [10]. The experience of 
Yemen with CQ resistance brought attention to the sig-
nificance of surveillance of the efficacy of anti-malarial 
drugs as a main activity of the NMCP.
In 2005, Yemen switched to artemisinin-based com-
bination therapy (ACT) for the treatment of uncompli-
cated falciparum malaria as per the recommendation 
of WHO [11]. The selection of the exact ACT is based 
on consideration of the options and the local resistance 
patterns for the partner drug [12, 13]. Efficacy trials 
done by the NMCP in Ibb in 2004 found that treatment 
failure rate after AQ monotherapy was 44  % and with 
AS + AQ 18.5 % (Adel Aljasary, pers. comm.). AS + AQ 
was excluded as an option in Yemen and led to selection 
of AS + SP as the first-line drug and AL as the second-
line drug for uncomplicated falciparum malaria (Adel 
Aljasary, pers. comm.).
AS + SP has been evaluated extensively in adults and 
children with uncomplicated malaria in other parts of 
the world and was found to be sufficiently efficacious in 
areas where 28-day cure rates with SP alone exceeded 
80 % [13, 14]. AL is currently one of the most widely used 
ACT for treatment of uncomplicated falciparum malaria. 
The previous four-dose regime was associated with 15 % 
treatment failure, but the now-recommended, six-dose 
regime has shown higher efficacy [15]. This paper pre-
sents the results of studies conducted to assess therapeu-
tic efficacy of AS + SP and AL against falciparum malaria 
in Yemen from 2009 to 2013. In addition, the impact of 
these two ACTs on microscopic gametocytaemia were 
evaluated in the study population. These studies were 
carried in the framework of monitoring therapeutic effi-
cacy of anti-malarial drugs.
Methods
Study design and patients
The studies were conducted in six sentinel sites repre-
senting the different malaria-endemic provinces of the 
country (see Fig.  1). Each study was timed to coincide 
with the peak of the malaria transmission in the area. The 
design of the study was an open-label, one-arm, prospec-
tive evaluation of clinical and parasitological responses to 
directly observed treatment for uncomplicated malaria. 
The WHO protocol for assessing therapeutic efficacy [16] 
was used. Cases were enrolled in the study, after obtain-
ing the patients’ or parents’/guardians’ written consent, 
if they were aged 6  months and above, had symptoms 
compatible with uncomplicated clinical malaria with 
fever (body temperature ≥37.5 °C) or history of fever in 
the previous 24  h and mono-infection of P. falciparum 
with parasite density of 500–200,000 asexual parasites/
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μl. A patient was excluded if she/he had a febrile illness 
other than malaria or severe and complicated falciparum 
malaria.
Pregnant women and females of reproductive age who 
could not be tested for pregnancy were  excluded. Preg-
nancy testing of unmarried women and female minors 
aged 12–17 years in Yemen is not acceptable according to 
the local customs and culture.
Treatment and laboratory analysis
The methods of treatment, follow-up and analysis of out-
comes was based on WHO guidelines [16]. After obtain-
ing a written informed consent, a complete medical 
history was obtained and a complete physical examina-
tion was performed. Blood was collected for microscopy 
and on filter paper on day 0 before treatment and on 
days 2, 3, 7, 14, 21, 28 or on any other day if the patient 
returned spontaneously.
Treatment regimen
All patients received a standard regimen of the drug 
being tested [12]. In the AS  +  SP studies the patients 
received a dose of 4 mg/kg/day artesunate once a day for 
3  days and a single administration of 25/1.25  mg/kg SP 
on day 0, with a therapeutic dose range between 2 and 
10 mg/kg/day artesunate and 25–70/1.25–3.5 mg/kg SP. 
In studies on AL, the patients were given AL (Coartem®, 
Novartis Pharmaceutical Corporation) according to body 
weight bands. Patients weighing 5–14  kg received one 
tablet (20 mg artemether plus 120 mg lumefantrine) per 
dose, those weighing 15–24 kg received two, those weigh-
ing 25–34  kg three tablets, and those weighing  ≥35  kg 
received four tablets. In total, six doses were adminis-
tered at hours 0, 8, 24, 36, 48, and 60. Study medications 
were provided by WHO. The intake of all doses of treat-
ment was directly observed. All drugs were within their 
expiry period, and batch number and expiry date were 
recorded in each case record form (CRF). If a patient 
vomited within 30 min of treatment, a full dose was re-
administered. All patients were followed up on days 1, 
2, 3, 7, 14, 21, and 28. On each of these follow-up visits 
clinical and parasitological assessments were repeated. 
Patients were also asked to report to the clinic at any time 
if new or recurrent symptoms occurred.
Fig. 1 Map of Yemen showing the sites of therapeutic efficacy studies of anti-malarial drugs against falciparum malaria in Yemen 2009–2013
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Rescue medication
All patients who failed to be cured with AS +  SP were 
treated with AL. Those who failed treatment with AL 
were treated with quinine orally at 10  mg salt/kg three 
times daily for 7 days.
Malaria microscopy
Thick and thin blood films for parasite counts were 
obtained from each patient and examined at screening 
and on days 2, 3, 7, 14, 21, 28 or on any other day if the 
patient returned spontaneously and parasitological reas-
sessment was required. Blood smears were stained with 
2.5 % Giemsa for 45 min and examined at a magnification 
of 1000×  to identify the parasite species and to deter-
mine the parasite density.
The thick blood smear was used to calculate the para-
site density, by counting the number of asexual parasites 
against 200 white blood cells (WBC) with a hand tally 
counter. The count was terminated when either 500 par-
asites or 200 WBC were reached, whichever came first. 
A blood smear was declared negative after examination 
of 1000 WBC revealed no asexual parasites. Parasite 
density, expressed as the number of asexual parasites 
per µl of blood, was calculated by dividing the number 
of asexual parasites by the number of WBC counted and 
then multiplying by an assumed WBC density of 8000 
per µl.
For quality assurance, all blood smears were re-read 
by a second microscopist. Blood smears with non-con-
cordant results (differences in species or differences in 
parasite density of >50 %) were re-read by a third micros-
copist and the average parasite density of the two most 
concordant counts was used.
Genotyping of malaria parasites
Two to three drops of blood were collected through 
finger pricks on filter paper (Whatmann No 3) during 
enrolment and each time blood smears were required, 
according to the protocol, on and after day 7. Specimens 
were labelled anonymously (Patient ID number, day of 
follow-up, date), kept in individual plastic bags with des-
iccant pouches and protected from light, humidity and 
extreme temperature until analysed. The specimens were 
genotyped to distinguish between recrudescence and 
new infections, according to methods recommended by 
WHO [17]. Blood spots were tested using nested poly-
merase chain reaction (PCR) targeting polymorphic vari-
ant genes msp1, msp2 (merozoite surface proteins) and 
glurp (glutamate-rich protein). Subsequently, gel analy-
sis was performed using Bionumerics V.5.10 in order to 
determine the size of the amplified gene targets. Iden-
tification of recrudescence and new infections was per-
formed according to WHO guidelines [17].
Classification of treatment outcome
Treatment outcomes were classified on the basis of an 
assessment of the parasitological and clinical outcome 
of anti-malarial treatment according to WHO guide-
lines [16]. A patient was classified as having either early 
treatment failure (ETF), late clinical failure (LCF), late 
parasitological failure (LPF), or an adequate clinical and 
parasitological response (ACPR), as defined in guidelines 
[16]. Patients who were lost to follow-up, had re-infec-
tions or unknown PCR were excluded from the per-pro-
tocol analysis of treatment outcomes, but included in the 
Kaplan–Meier analysis until the day of withdrawal from 
the study.
Drug tolerability and safety
Patients were assessed clinically for drug tolerability. 
Both adverse events and serious adverse events were 
monitored at enrolment and on each of the follow-up 
visit. An adverse event was defined as any untoward 
medical occurrence irrespective of its suspected rela-
tionship to the study medications. Serious adverse event 
included untoward medical occurrence requiring hospi-
talization or resulting in death.
Sample size and statistical analysis
The treatment failure rate of the two drugs in the study 
areas was estimated to be 5  %. At a confidence level of 
95 % and a precision estimate of 5 %, a minimum of 73 
patients had been planned to be enrolled in each site. 
With a 20 % increase to allow loss to follow-up and with-
drawals during the 28-day follow-up period, 87 patients 
were targeted to be included in the study per site per 
drug. Data were double entered and validated using a 
programme developed by WHO [16]. Per protocol and 
Kaplan–Meier survival analysis were used to evaluate the 
treatment outcome and only patients who could be eval-
uated on the respective days of follow-up were included 
in the analysis. The proportion of positive blood films on 
day 3 was recorded. Geometrical means of parasite den-
sity on day 0 were calculated for each site.
Statistical analysis was performed using SPSS 22® to 
generate descriptive statistics and analyse data (SPSS 
Inc. Chicago, USA). A 2 × 2 Chi square table was used to 
analyse associations between proportions using Epi-Info 
7 (Centers for Disease Control and Prevention, Atlanta, 
GA, USA and WHO, Geneva, Switzerland).
Ethical considerations
Permission to conduct the studies was obtained from 
the General Doctorate for Research and Studies, Min-
istry of Health, Yemen, which is the national body with 
oversight to ethically review research proposals involving 
human subjects, and WHO Ethical Research Committee. 
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Local authorities (community leaders) of the study areas 
were informed of the study objectives, procedures and 
duration and their permission was sought. Individual 
informed consent was obtained from adults and parents/
guardians of children. Those who were illiterate selected 
a witness not related to the research team to sign on their 
behalf.
Results
Eight therapeutic efficacy studies were conducted in six 
sentinel sites in Yemen to assess the therapeutic efficacy 
of AS  +  SP (five studies) and AL (three studies) dur-
ing the period November 2009 to March 2013. Table  1 
shows the demographic and clinical characteristics in 
the study population in each site. The age of patients 
ranged between 6 months and 75 years. The percentage 
of children under 5 years of age varied by study, ranging 
between 8.6 % in Tur Bani Qa’ is 2013 to 56 % in al-Udayn 
2010. There were also differences in gender composition 
in the different studies, the percentage of males ranged 
between 46.7 and 72 %. The mean temperature at base-
line showed variation ranging between 37.6 and 38.0  °C 
and the geometric mean asexual parasitaemia/µl varied 
from 1729 to 14,543/µl.
Table 2 shows details of the outcomes of all the studies. 
In the AS + SP studies, a total of 465 patients with falci-
parum malaria who satisfied the inclusion criteria were 
enrolled. The study was completed by 432 patients, with 
426 cases classified on day 28 as ACPR. There were three 
LCF and two LPF. In addition, there were ten patients lost 
to follow-up and 24 withdrawals. The reasons for with-
dawal were quality control detecting that parasite count 
at baseline was too low (18 cases), mixed infection (two 
cases), underdose (one case), and withdrawal of consent 
by patient (three cases). According to the follow-up and 
analysis plan, cases initially classified as LCF or LPF were 
checked by PCR to differentiate recrudescence from 
re-infection. PCR-correction confirmed recrudescence in 
two of the LCF cases.
In the individual studies and after PCR-correction 
Kaplan–Meier analysis, the cure rate with AS  +  SP 
ranged between 98 and 100 % in the different sites. The 
two cases of treatment failure were in Bajil 2013. The first 
case (LCF) was a 2 year old male who presented on day 
28 with a history of fever, his blood film showed 880 P. 
falciparum asexual stages/µl. The second case (LCF) was 
a 5 year old female who presented on day 28 with a recent 
history of fever and her blood film was positive with 
45,454 P. falciparum asexual stages/µl. Both cases had 
treatment doses within the therapeutic range.
In the AL studies, a total of 268 patients with falcipa-
rum malaria satisfied the inclusion criteria (Table 1). The 
studies were completed by 252 patients with 245 cases 
classified on day 28 as ACPR, two cases as LPF in Jabal-
Al-Sharq 2010, and five cases in Tor-Bani-Qa’is as LCF. 
In addition, there were six patients lost to follow-up and 
ten withdrawals. The reasons for withdrawal was quality 
control detecting low baseline parasitaemia (seven cases) 
and withdrawal of consent (three cases). According to 
the follow-up and analysis plan, cases initially classified 
as LCF or LPF were checked by PCR for recrudescence 
or re-infection, which found the five cases initially clas-
sified at LCF in Tur-Bani-Qa’is to be re-infections; the 
two cases initially classified as LPF (from Jabal-Al-sharq) 
were excluded from the PCR-corrected analysis because 
they had unknown PCR. In the PCR-corrected analysis 
and after Kaplan–Meier analysis, the cure rate following 
AL was 100 % in all the three sites tested. All cases except 
one had cleared asexual parasitaemia by day 3. Details of 
the PCR-uncorrected treatment failure cases were as fol-
lows: the first one was a 4 year-old female, who presented 
with history of fever and with 1400 asexual stages/µl on 
day 0. Low parasite count persisted on day 2 (520 asexual 
stages/µl), day 3 (320 asexual stages/µl) and day 7, when 
Table 1 Patient characteristics on admission, Yemen (2010–2013)
a Febrile patients: axillary temp ≥ 37.5 °C
Drug Site Year n Males (%) Age <5 years Temp °C Febrile patientsa ≥37.5
n (%)
Parasitaemia (/μL)
n (%) 95 % CI Mean (SD) Geometric mean (95 % CI)
AS + SP Al-Udayn 2010 85 44 (51.8) 48 (56.5) (45.3–67.2) 37.9 (0.2) 70 (82.4) 3429 (2643–4449)
AS + SP Sharas 2010 93 52 (55.9) 31 (33.3) (23.9–43.9) 37.7 (0.1) 56 (60.2) 9088 (6947–11,890)
AS + SP Tur Bani Qa’is 2010 95 58 (61.1) 38 (40) (30.1–50.6) 37.9 (0.3) 75 (78.9) 14543 (10,325–18,628)
AS + SP Al Qaflaha 2011 90 42 (46.7) 33 (36.7) (26.7–47.5) 37.6 (0.7) 55 (61.1) 3238 (2506–4184)
AS + SP Bajil 2013 102 51 (50.0) 10 (9.8) (4.8–17.3) 38.0 (0.4) 45 (44.1) 7011 (5461–8999)
AL Bajil 2009–10 80 43 (53.8) 7 (8.8) (3.6–17.2 37.6 (0.4) 74 (92.5) 12,606 (8707–18,248)
AL Jabal Al Sharq 2010 95 57 (60.0) 14 (14.7) (8.3–23.5) 37.6 (0.3) 57 (60) 1729 (1399–2137)
AL Tur Bani Qa’is 2013 93 67 (72.0) 8 (8.6) (3.8–16.2) 38.0 (0.1) 81 (87.1) 11,872 (8698–16,203)
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the parasite count went up to 5502 asexual stages/µl. She 
was classified as LPF, and because her PCR was negative 
on day 7 she was excluded in the PCR-corrected classifi-
cation. This was the only case that had microscopic para-
sitaemia on day 3. The second case was a 7 year old, who 
presented with history of fever, parasite density on day 0 
was 1200 asexual stages/µl, and had adequate resolution 
of fever and microscopic parasitaemia but on day 21 the 
parasite count was 7000 asexual stage/µl. The patient was 
classified as LPF but excluded from the PCR classifica-
tion because the PCR was not known. The five cases of 
LCF in Tur-Bani-Qa’is were all children between 6 and 
10 years old, who presented with fever and positive blood 
film on day 21 (one case) and day 28 (four cases). PCR 
analysis classified all five cases as re-infections. All thera-
peutic regimens of the two study drugs were well toler-
ated and safe.
Figure  2 is a Kaplan–Meier plot (survival analysis) 
showing gametocyte clearance times in patients who 
were gametocytaemic at enrolment, after treatment with 
AL (n =  42) and with AS +  SP group (n =  91). By day 
7, after treatment the proportion with gametocytaemia 
was significantly lower in the AL group compared with 
the ASSP group [20/42 (47.6  %) versus 68/91 (74.7  %), 
Chi =  9.432, P =  0.002]. This higher gametocyte clear-
ance rate was observed at the follow-up visits on days 
14, 21 and 28. Among the patients who were negative for 
gametocytes at baseline, more patients in the AS  +  SP 
group developed gametocytaemia after treatment than 
in the AL group, 22/342 (6.4  %) versus 5/214 (2.3  %), 
respectively, P = 0.041, Fisher’s exact test.
Discussion
The 28-day parasitological cure observed after first-line 
AS + SP therapy in the present study exceeded 95 % in all 
the sites after PCR-correction and also in the uncorrected 
analyses, meeting the WHO recommendation that cure 
rates for falciparum malaria should be at least 90 % and 
preferably  >95  %. Detection of asexual parasites on day 
3 is an early warning sign of slow clearance of parasites 
by artemisinin [18, 19]. In the present study, the complete 
clearance of asexual parasitaemia in all cases on day 3 
after treatment with AS + SP was an indication that the 
artesunate component is still effective. Since the blood 
levels of the drugs in the patients were note measured, it 
cannot be ruled out that these two cases had lower blood 
levels of the drugs. The SP dose was developed for adults 
but in the main target group (children aged 2–5  years) 
the weight-adjusted dose produced blood concentrations 
of both components that are approximately half of those 
in adults [20]. This means that the standard dose may be 
sub-optimal in younger children. Although in the present 
study AS  +  SP shows high efficacy resulting in a high 
cure rate, there is still a need for close monitoring of the 
therapeutic efficacy of this ACT in Yemen. Resistance to 
the SP component drugs are easy to induce experimen-
tally [21]. In Africa SP resistance developed soon after 
the drug was adopted as first-line treatment against fal-
ciparum malaria [22]. This has been attributed mainly 
to the long elimination half-life of the SP components, 
which make it much easier for resistance to develop to 
this drug compared to the more rapidly eliminated anti-
malarials [23]. The pattern of use of anti-malarial drugs is 
believed to be a major factor in the emergence and spread 
of anti-malarial drug resistance [24]. Nevertheless, it is 
notable that despite high rates of self-medication, incom-
plete treatments and sub-standard drugs, the efficacy of 
AS + SP remains high in Yemen, as shown in the present 
results [11, 25, 26].
The findings of high efficacy of AS + SP against falci-
parum malaria are supported by the fact that at present 
there is no evidence that SP has lost its efficacy against 
falciparum malaria in Yemen. In 2005, in vivo and in vitro 
tests were conducted by Al-Kabsi et  al. to determine 
the SP efficacy against P. falciparum isolates from 100 
malaria patients in Tihamah, Yemen [27]. In the in vivo 
test, no clinical or parasitological failure occurred. The 
in  vitro test results suggested that SP is still effective 
against P. falciparum in the study area.
Published studies with SP resistance-associated molec-
ular markers in Yemen are few and have not provided 
consistent results about the prevalence of these mark-
ers. A molecular marker study in Meseimeer found a 
5 % prevalence of dhfr Arg-59 mutation in 99 amplified 
samples, while the dhps Glu-540 was not detected in 119 
Fig. 2 Time to disappearance of microscopic gametocytaemia in 
gametocyte-positive individuals at enrolment and following treat-
ment. AL artemether-lumefantrine (n = 42), AS + SP sulfadoxine-
pyrimethamine (n = 91)
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amplified samples [6, 7]. This was interpreted to suggest 
that the selection process had not reached dhps [6]. In a 
more recent work [28], four drug-resistant genes (pfcrt, 
pfmdr1, dhfr, and dhps) were genotyped in 108 P. falcipa-
rum isolates collected in three sites in Yemen: Dhamar, 
Hodeidah and Taiz. The investigators concluded that the 
absence of the triple mutant dhfr genotype (IRN) and 
dhps mutations supports the use of AS + SP as first-line 
therapy. They suggested that the previous report on the 
presence of C59 mutation could possibly be explained 
by inclusion of expatriates in the sample of patients 
studied. In another study, isolates from 90 patients with 
microscopically confirmed P. falciparum infection from 
Al-Hodaida were analysed for the molecular dhfr 108 N 
by Abdul-Ghani et  al. [29]. The mutation was detected 
among about 61  % of P. falciparum isolates in its pure 
and mixed-type forms. They suggested that the high 
frequency of dhfr 108  N among parasite isolates should 
be cause for concern about the efficacy of SP as partner 
with AS. However, dhfr 108 mutation is a first step and 
is followed by other mutations before significant resist-
ance occurs [30]. The high prevalence of SP resistance-
associated genotypes reported from Sudan [31] and other 
countries in the region, such as Ethiopia [32] and Somalia 
[33], calls for close monitoring for the emergence of these 
genotypes in Yemen.
In the present study, the 28-day, PCR-uncorrected cure 
rate after treatment with AL is 100  % in Bajil (95  % CI 
95.1–100 %), in Jabal-Al-Sharq it is 97.8 % (95 % CI 92.2–
99.7 %) and in Tur Bani Qa’is it is 94.3 % (95 % CI 87.2–
98.1 %). The PCR-corrected, 28-day cure rate after AL in 
each of the three sites is 100  %. This is higher than the 
findings of a recently pooled analysis of a 28-day, PCR-
corrected parasitological cure rate of 97.1 % in adults and 
97.3  % in children [34]. The two cases classified as LPF 
in Jabal-Al-Sharq study in the uncorrected analysis (PCR 
was not done) could be explained by low bio-availability 
of the drug but drug blood levels have not been done to 
confirm.
The effect of AL in the present study on microscopic 
gametocytaemia is consistent with findings from other 
endemic areas, which show a significant impact of AL 
on gametocytaemia [35]. The data also demonstrate 
the superior efficacy of AL over AS  +  SP in clearance 
of microscopic gametocytaemia. This could be a factor 
in choosing between different ACT in the future, par-
ticularly in an area of low transmission, on the path to 
malaria elimination.
Conclusions
AS + SP remains a safe and effective first-line drug for the 
treatment of uncomplicated falciparum malaria in Yemen. 
However, monitoring the efficacy of this ACT should be 
continued since there is a high risk of failure of the SP 
component due to sub-therapeutic levels resulting from 
inadequate use of anti-malarial drugs in the country. Sur-
veillance for SP resistance-associated molecular markers 
should also be monitored as a supportive tool to in  vivo 
efficacy. AL is highly efficacious in Yemen and remains the 
appropriate option as a second-line treatment for uncom-
plicated falciparum malaria. AL shows higher efficacy than 
AS + SP in the clearance of microscopic gametocytaemia.
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